GH Research PLC (NASDAQ:GHRS) Sees Large Growth in Short Interest

GH Research PLC (NASDAQ:GHRS - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 1,450,000 shares, an increase of 10.7% from the March 31st total of 1,310,000 shares. Approximately 5.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 127,200 shares, the days-to-cover ratio is presently 11.4 days.

GH Research Stock Performance

Shares of NASDAQ:GHRS traded up $0.99 during mid-day trading on Wednesday, hitting $11.95. The stock had a trading volume of 117,065 shares, compared to its average volume of 128,173. The company's 50 day moving average is $10.13 and its 200-day moving average is $7.93. GH Research has a 12-month low of $5.05 and a 12-month high of $14.64. The company has a market cap of $621.76 million, a PE ratio of -17.57 and a beta of 0.84.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its earnings results on Thursday, February 29th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). On average, equities research analysts predict that GH Research will post -0.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GHRS has been the subject of a number of recent research reports. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of GH Research in a research report on Monday, March 4th. JMP Securities dropped their price target on GH Research from $50.00 to $39.00 and set a "market outperform" rating on the stock in a research note on Friday, March 1st.

Hedge Funds Weigh In On GH Research

Institutional investors and hedge funds have recently bought and sold shares of the business. PEAK6 Investments LLC grew its position in GH Research by 72.9% during the third quarter. PEAK6 Investments LLC now owns 40,308 shares of the company's stock valued at $405,000 after purchasing an additional 16,991 shares in the last quarter. AdvisorShares Investments LLC raised its holdings in shares of GH Research by 4.3% during the fourth quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company's stock worth $280,000 after acquiring an additional 1,977 shares in the last quarter. Barclays PLC boosted its position in GH Research by 98.2% during the third quarter. Barclays PLC now owns 63,590 shares of the company's stock valued at $640,000 after purchasing an additional 31,500 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in GH Research by 16.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 92,784 shares of the company's stock valued at $932,000 after purchasing an additional 12,911 shares in the last quarter. Finally, Lynx1 Capital Management LP increased its position in GH Research by 13.8% in the 3rd quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company's stock worth $11,087,000 after purchasing an additional 133,804 shares during the last quarter. Hedge funds and other institutional investors own 56.90% of the company's stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.